Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Number To Know…37

Executive Summary

An experimental deep-brain stimulation treatment has demonstrated it can reduce tic severity in Tourette's syndrome patients by 37%.

37% is the average drop in tic severity in Tourette's Syndrome patients achieved in a study to evaluate an experimental deep-brain stimulation (DBS) procedure by New York University's Langone Medical Center. The NYU team investigated thalmic DBS, wherein two electrodes were inserted in patients' medial thalamus. The thalamus is the part of the brain that "functions abnormally" in people with Tourette's syndrome. At six months, all patients reported that their symptoms improved "much" or "very much."

Meddevicetracker subscribers can access a full analysis of NYU Langone Medical Center's product portfolio, including the clinical and regulatory status of the Thalamic DBS, here.

Not a subscriber? Click here to request your free demo.

Topics

UsernamePublicRestriction

Register

MT104726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel